Saturday, October 12, 2024 7:13:33 PM
GGB, what you're bringing up fits nicely into the discussion of problems, and non-problems.
In most cases, when a problem is solved, that ends discussion of it. During the many years the company has been in business, many problems have been resolved.
Non-problems can never be fully resolved, because people just keep asking, in spite the fact that they were either never a problem, or were, but were completely resolved. No answer is deemed to be sufficient.
Things like, When was the last time you beat your wife? No answer is forever.
In the case of NWBO many problems have been resolved by working with the regulators to modify how the trial was to be run and evaluated. No company discloses all the changes they make with the concurrence of the regulators, they put out modified guidance, but they don't say all that went into arriving at it.
While the problem has been resolved, in NWBO's case, the resolved problems answer isn't fully accepted, so it just becomes a non-problem.
Things like UCLA's vaccine not being DCVax-L, or the trial being for PFS, just never go away. These non-problems just keep being asked, and answered, but there is always someone who asks it again. Perhaps if the company answered it might be accepted, but the company simply isn't going to tell investors about all the discussions they have with the regulators, etc., and how they're resolved.
Gary
In most cases, when a problem is solved, that ends discussion of it. During the many years the company has been in business, many problems have been resolved.
Non-problems can never be fully resolved, because people just keep asking, in spite the fact that they were either never a problem, or were, but were completely resolved. No answer is deemed to be sufficient.
Things like, When was the last time you beat your wife? No answer is forever.
In the case of NWBO many problems have been resolved by working with the regulators to modify how the trial was to be run and evaluated. No company discloses all the changes they make with the concurrence of the regulators, they put out modified guidance, but they don't say all that went into arriving at it.
While the problem has been resolved, in NWBO's case, the resolved problems answer isn't fully accepted, so it just becomes a non-problem.
Things like UCLA's vaccine not being DCVax-L, or the trial being for PFS, just never go away. These non-problems just keep being asked, and answered, but there is always someone who asks it again. Perhaps if the company answered it might be accepted, but the company simply isn't going to tell investors about all the discussions they have with the regulators, etc., and how they're resolved.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
